GGrantIndex
← Leaderboards

Branimir I Sikic

Stanford University

Google Scholar ↗PubMed ↗ORCID ↗
$8,041,001
Attributed
$11,143,693
Total exposure
20
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY2005–18
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$11,143,693 · 20

By mechanism

R01$5,461,102 · 4
U10$2,779,160 · 1
M01$1,373,567 · 13
R33$1,069,524 · 1
P30$460,340 · 1

Top collaborators

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research”

Research focus

Clinical ResearchHuman SubjectNeoplasm /Cancer ChemotherapyHuman Therapy EvaluationPaclitaxelClinical Trial Phase ICombination ChemotherapyMultidrug ResistanceResearch PersonnelMalignant NeoplasmsP GlycoproteinDrug Screening /EvaluationCyclosporinesPharmaceutical PreparationsProgramsGrowthAntisense Nucleic AcidClinical TrialsSpecimenPharmacokineticsGene ExpressionCollaborationsInterestBreast

Grant awards (61)

Stanford University NCTN- Network Lead Academic Site$518,824
U10 · FY2018 · CA
Stanford University NCTN- Network Lead Academic Site$547,394
U10 · FY2017 · CA
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2017 · CA · contact PI
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2016 · CA · contact PI
Stanford University NCTN- Network Lead Academic Site$490,000
U10 · FY2016 · CA
Stanford University NCTN- Network Lead Academic Site$576,471
U10 · FY2015 · CA
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2015 · CA · contact PI
Stanford University NCTN- Network Lead Academic Site$70,000
U10 · FY2015 · CA
Stanford University NCTN- Network Lead Academic Site$576,471
U10 · FY2014 · CA
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2014 · CA · contact PI
Protocol Specific Research Support$117,669
P30 · FY2014 · CA · contact PI
Protocol Specific Research Support$78,011
P30 · FY2013 · CA · contact PI
Protocol Specific Research Support$83,355
P30 · FY2012 · CA · contact PI
Taxane Resistance in Breast and Ovarian Cancer Cells$288,798
R01 · FY2011 · CA · contact PI
Protocol Specific Research Support$85,297
P30 · FY2011 · CA · contact PI
Taxane Resistance in Breast and Ovarian Cancer Cells$297,730
R01 · FY2010 · CA · contact PI
Protocol Specific Research Support$96,008
P30 · FY2010 · CA · contact PI
Taxane Resistance in Breast and Ovarian Cancer Cells$297,730
R01 · FY2009 · CA · contact PI
Taxane Resistance in Breast and Ovarian Cancer Cells$297,730
R01 · FY2008 · CA · contact PI
Taxane Resistance in Breast and Ovarian Cancer Cells$312,009
R01 · FY2007 · CA · contact PI
STUDY OF OBLIMERSEN (GENASENSETM, G3139) IN ADVANCED MALIGNANCIES$11,119
M01 · FY2006 · RR · contact PI
Regulation of the Human MDR1 Gene$279,460
R01 · FY2005 · CA
STUDY OF OBLIMERSEN IN COMBINATION WITH GEMCITABINE IN ADVANCED MALIGNANCIES$57,802
M01 · FY2005 · RR
TREATMENT OF ADVANCED SOLID MALIGNANCIES$43,769
M01 · FY2005 · RR
Regulation of the Human MDR1 Gene$279,460
R01 · FY2004 · CA
A Phase I Study of ZD1839 (Iressa TM) with Oxaliplatin$122,084
M01 · FY2004 · RR
Phase I Study of BMS-310705 Given Every Three Weeks$34,669
M01 · FY2004 · RR
A Phase I Study of Oblimersen (Genasense TM, G3139)$22,817
M01 · FY2004 · RR
Phase I Study: Weekly BMS-188797 Alone &with Carboplat$889
M01 · FY2004 · RR
GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS$380,741
R33 · FY2003 · CA
Regulation of the Human MDR1 Gene$279,460
R01 · FY2003 · CA
GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS$301,055
R33 · FY2002 · CA
Regulation of the Human MDR1 Gene$279,460
R01 · FY2002 · CA
MODULATION OF MULTIDRUG RESISTANCE MECHANISMS$110,791
R01 · FY2002 · CA
GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS$387,728
R33 · FY2001 · CA
MODULATION OF MULTIDRUG RESISTANCE MECHANISMS$355,604
R01 · FY2001 · CA
PHASE I TRIAL OF DOXORUBICIN, PACLITAXEL, AND PSC 833$134,676
M01 · FY2001 · RR
PHASE I TRIAL OF DOXIL, PACLITAXEL AND VALSPODAR PSC 833$134,676
M01 · FY2001 · RR
LY335979 &MITOXANTRONE IN PROSTATE CANCER$134,676
M01 · FY2001 · RR
PHASE I TRIAL OF ANTISENSE INHIBITOR OF PROTEIN KINASE C ALPHA IN CAN$134,676
M01 · FY2001 · RR
PHASE I PROTEIN KINASE, CARBOPLATIN AND PACLITAXEL CHEMO. FOR CANCER$134,676
M01 · FY2001 · RR
PHASE II OF ISIS 3521 IN PATIENTS WITH OVARIAN CARCINOMA$134,676
M01 · FY2001 · RR
PACLITAXEL AND PSC 833 IN METASTATIC COLORECTAL CARCINOMA$134,676
M01 · FY2001 · RR
PHASE I TRIAL OF ORAL PACLITAXEL AND VALSPODAR (PSC 833)$134,676
M01 · FY2001 · RR
PHASE I TRIAL OF DOXORUBICIN, PACLITAXEL, AND PSC 833$0
M01 · FY2001 · RR
PHASE I TRIAL OF ORAL PACLITAXEL AND VALSPODAR (PSC 833)$0
M01 · FY2001 · RR
PHASE I TRIAL OF DOXIL, PACLITAXEL AND VALSPODAR PSC 833$0
M01 · FY2001 · RR
LY335979 &MITOXANTRONE IN PROSTATE CANCER$0
M01 · FY2001 · RR
PHASE I TRIAL OF ANTISENSE INHIBITOR OF PROTEIN KINASE C ALPHA IN CAN$0
M01 · FY2001 · RR
PHASE I PROTEIN KINASE, CARBOPLATIN AND PACLITAXEL CHEMO. FOR CANCER$0
M01 · FY2001 · RR
PHASE II OF ISIS 3521 IN PATIENTS WITH OVARIAN CARCINOMA$0
M01 · FY2001 · RR
PACLITAXEL AND PSC 833 IN METASTATIC COLORECTAL CARCINOMA$0
M01 · FY2001 · RR
MODULATION OF MULTIDRUG RESISTANCE MECHANISMS$346,226
R01 · FY2000 · CA
PACLITAXEL AND PSC 833 IN METASTATIC COLORECTAL CARCINOMA$602
M01 · FY2000 · RR
PHASE I PROTEIN KINASE, CARBOPLATIN AND PACLITAXEL CHEMO. FOR CANCER$602
M01 · FY2000 · RR
PHASE II OF ISIS 3521 IN PATIENTS WITH OVARIAN CARCINOMA$602
M01 · FY2000 · RR
PHASE I TRIAL OF DOXORUBICIN, PACLITAXEL, AND PSC 833$602
M01 · FY2000 · RR
PHASE I TRIAL OF ANTISENSE INHIBITOR OF PROTEIN KINASE C ALPHA IN CAN$602
M01 · FY2000 · RR
PHASE I TRIAL OF ORAL PACLITAXEL AND VALSPODAR (PSC 833)$0
M01 · FY2000 · RR
PHASE I TRIAL OF DOXIL, PACLITAXEL AND VALSPODAR PSC 833$0
M01 · FY2000 · RR
LY335979 &MITOXANTRONE IN PROSTATE CANCER$0
M01 · FY2000 · RR